Zhejiang Hisun Pharmaceutical (600267.SH): Tacrolimus capsules and four other products are proposed to be selected for centralized bulk procurement.

Zhejiang Hisun Pharmaceutical (600267.SH) announced that on July 31, 2026, the company and its wholly-owned subsidiary Hanhui Pharmaceutical Co., Ltd. (referred to as "Hanhui Pharmaceutical") participated in the bidding organized by the Joint Procurement Office for the twelfth batch of national centralized procurement of pharmaceuticals. According to the "Announcement of Proposed Selected Results for the Twelfth Batch of National Organized Procurement of Pharmaceuticals" released by the Joint Procurement Office that evening, the company and its wholly-owned subsidiary Hanhui Pharmaceutical are proposed to be selected for five products that fall within the scope of this centralized procurement. The companys injectable Doxorubicin Hydrochloride, Injectable Vancomycin Hydrochloride, Injectable Imipenem and Cilastatin Sodium, Injectable Teicoplanin, and Tacrolimus Capsules have passed the consistency evaluation of quality and efficacy for generic drugs in March 2021, November 2021, July 2023, July 2024, and September 2025, respectively. The total sales revenue of the proposed selected products for the year 2025 is expected to be 426 million yuan, accounting for approximately 4.04% of the company's operating revenue for 2025. In this twelfth batch of national organized centralized procurement, the proposed selected prices of the company show a certain degree of decrease compared to the original local average selected prices. If confirmed as selected, this will benefit the above products in expanding their domestic sales market, increasing market share, promoting the further development of the companys formulation business, enhancing the company's brand influence, and providing quality products at reasonable prices to the market.